PARIS, France – 12 March 2020 – Lysogene (FR0013233475 – LYS), a pioneering Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced the successful completion of a capital increase, issuing 2,731,251 new ordinary shares representing 20% of its share capital prior to the capital increase, at a subscription price of…

17th patient dosed in the ongoing phase 2/3 AAVance study PARIS, France – 25 February 2020 – Lysogene (FR0013233475 – LYS), a pioneering Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its LYS-SAF302 program for…

Cash and cash equivalent of €26.5 million1 as of 31 December 2019 PARIS, France – 17 February 2020 – Lysogene (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today reports its cash position as of 31 December 2019. As of 31 December 2019, cash…

Paris, France — 11 February 2020 — Lysogene (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today announced its participation to the upcoming 16th WORLDSymposium™ on Lysosomal Diseases to be held February 10 – 13, 2020 in Orlando, FL, USA. Platform presentation: Phase 2-3…

Reminder of the other communications expected in the 1st Half of 2020 PARIS (France), 24 January 2020 – Lysogene (FR0013233475 – LYS) today announced its corporate agenda* for 2020: 17 February 2020: Sales and cash position at the end of 2019 20 March 2020: 2019 annual results 22 April 2020: First quarter 2020 sales and…

PARIS – December 18, 2019 at 06:00pm – Lysogene (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today announced the publication of a scientific article describing preclinical work performed with LYS-SAF302, a drug candidate currently in a phase II/III clinical trial (NCT03612869) for the…

PARIS – December 18, 2019 at 06:00pm – Lysogene (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today announced the publication of a scientific article describing preclinical work performed with LYS-SAF302, a drug candidate currently in a phase II/III clinical trial (NCT03612869) for the…

Cash and cash equivalent of €29.1 million1 as of 30 September 2019 PARIS, France, – 20 November 2019, at 7:30am CET – Lysogene (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today reports its cash position as of 30 September 2019. As of 30…

PARIS – October 17, 2019 at 06:00 pm – Lysogene (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today announced the appointment of Stéphane Durant des Aulnois as Chief Financial Officer. In this position, Stéphane will supervise all financial activities, as well as Alliance…

Cash and cash equivalent of €33.2 million as of June 30, 2019 On track for full patient inclusion (11 out of 20 patients included) in the MPS IIIA AAVance Phase 2-3 gene therapy study of LYS-SAF302 On target to submit the Phase 1-2 GM1 gangliosidosis clinical trial IND at end 2019 Signature of a cooperation…